Congenital schizencephaly associated with in utero warfarin exposure.
The warfarin embryopathy is a well-defined complex of fetal anomalies generally accepted to result from first trimester exposure. Optic atrophy and dilation of the cerebral cerebral ventricles associated with blindness, microcephaly, and mental retardation have been reported following second and third trimester exposure. In contrast to the consistent clinical features observed in the warfarin embryopathy, the CNS effects seen in fetuses exposed in the later trimesters share little in terms of specific lesion or long-term clinical outcome. A case of schizencephaly in a coumadin-exposed fetus is presented. This report offers supportive evidence that the CNS sequellae of this agent are the result of vascular accident and hemorrhage, not a direct effect on CNS morphogenesis. The molecular basis for the adverse effects of warfarin derivatives on the fetus are reviewed. Warfarin derivatives exert both their embryopathic and their fetopathic effects via pharmacologic action: inhibition of gamma carboxylation of osteocalcin and a similar carboxylation of the vitamin K dependent clotting factors. Therefore, we believe that warfarin exposure in the second or third trimesters of pregnancy is equally dangerous to the fetus as that in the first. Heparin may be a superior alternative to warfarin for the prevention of thromboembolic disease in pregnant women with cardiac valve prostheses.
Department of Obstetrics and Gynecology, Georgetown University Medical Center, Washington, DC 20007.
S
S
Pati
G D
GD
Helmbrecht
D000014:Abnormalities, Drug-Induced / Q000196:embryology / Q000209:etiology*; D000328:Adult; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001921:Brain / Q000002:abnormalities*; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D014859:Warfarin / Q000009:adverse effects*
D014859:Warfarin